These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1434 related articles for article (PubMed ID: 34726142)

  • 1. Symptom monitoring after coronavirus disease 2019 (COVID-19) vaccination in a large integrated healthcare system: Separating symptoms from severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection.
    Shenoy ES; Wickner PG; West LR; Banerji A; Blumenthal KG; Centi AJ; Gottlieb A; Hashimoto DM; Kim E; Kim M; Lee H; Simpson LA; Landman AB
    Infect Control Hosp Epidemiol; 2022 Oct; 43(10):1439-1446. PubMed ID: 34726142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disentangling post-vaccination symptoms from early COVID-19.
    Canas LS; Österdahl MF; Deng J; Hu C; Selvachandran S; Polidori L; May A; Molteni E; Murray B; Chen L; Kerfoot E; Klaser K; Antonelli M; Hammers A; Spector T; Ourselin S; Steves C; Sudre CH; Modat M; Duncan EL
    EClinicalMedicine; 2021 Dec; 42():101212. PubMed ID: 34873584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Timing of last COVID-19 vaccine dose and SARS-CoV-2 breakthrough infections in fully (boosted) vaccinated healthcare personnel.
    Maltezou HC; Gamaletsou MN; Giannouchos TV; Koukou DM; Karapanou A; Sourri F; Syrimi N; Lemonakis N; Peskelidou E; Papanastasiou K; Souliotis K; Lourida A; Panagopoulos P; Hatzigeorgiou D; Sipsas NV
    J Hosp Infect; 2023 Feb; 132():46-51. PubMed ID: 36473554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptoms and symptom clusters associated with SARS-CoV-2 infection in community-based populations: Results from a statewide epidemiological study.
    Dixon BE; Wools-Kaloustian K; Fadel WF; Duszynski TJ; Yiannoutsos C; Halverson PK; Menachemi N
    medRxiv; 2020 Oct; ():. PubMed ID: 33106813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
    Fabiani M; Puopolo M; Morciano C; Spuri M; Spila Alegiani S; Filia A; D'Ancona F; Del Manso M; Riccardo F; Tallon M; Proietti V; Sacco C; Massari M; Da Cas R; Mateo-Urdiales A; Siddu A; Battilomo S; Bella A; Palamara AT; Popoli P; Brusaferro S; Rezza G; Menniti Ippolito F; Pezzotti P;
    BMJ; 2022 Feb; 376():e069052. PubMed ID: 35144968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 in Health Care Personnel: Significance of Health Care Role, Contact History, and Symptoms in Those Who Test Positive for SARS-CoV-2 Infection.
    Lepak AJ; Buys A; Stevens L; LeClair-Netzel M; Anderson L; Osman F; Brennan MB; Bartels CM; Safdar N
    Mayo Clin Proc; 2021 Sep; 96(9):2312-2322. PubMed ID: 34366140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presence of symptoms 6 weeks after COVID-19 among vaccinated and unvaccinated US healthcare personnel: a prospective cohort study.
    Mohr NM; Plumb ID; Harland KK; Pilishvili T; Fleming-Dutra KE; Krishnadasan A; Hoth KF; Saydah SH; Mankoff Z; Haran JP; Briggs-Hagen M; León ES; Talan DA;
    BMJ Open; 2023 Feb; 13(2):e063141. PubMed ID: 36731936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination and Booster on Coronavirus Disease 2019 (COVID-19) Symptom Severity Over Time in the COVID-OUT Trial.
    Boulware DR; Murray TA; Proper JL; Tignanelli CJ; Buse JB; Liebovitz DM; Nicklas JM; Cohen K; Puskarich MA; Belani HK; Siegel LK; Klatt NR; Odde DJ; Karger AB; Ingraham NE; Hartman KM; Rao V; Hagen AA; Patel B; Fenno SL; Avula N; Reddy NV; Erickson SM; Lindberg S; Fricton R; Lee S; Zaman A; Saveraid HG; Tordsen WJ; Pullen MF; Sherwood NE; Huling JD; Bramante CT;
    Clin Infect Dis; 2023 Feb; 76(3):e1-e9. PubMed ID: 36124697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infections and Incidence of the Presumptive B.1.427/B.1.429 Variant Among Healthcare Personnel at a Northern California Academic Medical Center.
    Jacobson KB; Pinsky BA; Montez Rath ME; Wang H; Miller JA; Skhiri M; Shepard J; Mathew R; Lee G; Bohman B; Parsonnet J; Holubar M
    Clin Infect Dis; 2022 Mar; 74(5):821-828. PubMed ID: 34137815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Value of Isolated Symptoms for Diagnosis of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children Tested During Peak Circulation of the Delta Variant.
    Westbrook AL; Benedit LC; Frediani JK; Griffiths MA; Khan NY; Levy JM; Morris CR; Rostad CA; Stone CL; Sullivan J; Vos MB; Welsh J; Wood A; Martin GS; Lam W; Pollock NR
    Clin Infect Dis; 2022 Sep; 75(7):1131-1139. PubMed ID: 35271694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.
    Accorsi EK; Britton A; Fleming-Dutra KE; Smith ZR; Shang N; Derado G; Miller J; Schrag SJ; Verani JR
    JAMA; 2022 Feb; 327(7):639-651. PubMed ID: 35060999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of vaccinations and breakthrough infections after adjustment of the dynamic zero-COVID-19 strategy in China: an online survey.
    Qin S; Li Y; Wang L; Zhao X; Ma X; Gao GF
    Emerg Microbes Infect; 2023 Dec; 12(2):2258232. PubMed ID: 37691586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The seroprevalence of SARS-CoV-2 in a rural southwest community.
    Santarelli A; Lalitsasivimol D; Bartholomew N; Reid S; Reid J; Lyon C; Wells J; Ashurst J
    J Osteopath Med; 2021 Feb; 121(2):199-210. PubMed ID: 33567087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID.
    Weaver KN; Zhang X; Dai X; Watkins R; Adler J; Dubinsky MC; Kastl A; Bousvaros A; Strople JA; Cross RK; Higgins PDR; Ungaro RC; Bewtra M; Bellaguarda E; Farraye FA; Boccieri ME; Firestine A; Kappelman MD; Long MD
    Inflamm Bowel Dis; 2022 Oct; 28(10):1497-1505. PubMed ID: 34871388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 72.